Staircase diagram comparing the risk of ESRD (above) versus malignancy (below). Values are OR (95% CrI).
| Corticosteroid | 0.49 (0.25–0.92) | 0.60 (0.26–1.36) | 0.25 (0.06–1.04) |
| 1.36 (0.11–1.50) | Cyclophosphamide | 1.23 (0.58–2.60) | 0.51 (0.12–2.01) |
| 4.17 (0.33–221.3) | 3.13 (0.56–20) | Azathioprine | 0.42 (0.11–1.51) |
| 0.83 (0.04–50) | 0.59 (0.08–3.45) | 0.19 (0.02–1.08) | Mycophenolate mofetil |
We report only the OR of treatment comparisons common to both outcomes. This diagram is read diagonally from top to bottom with the top treatment always serving as the reference treatment. For instance, the table illustrates that the OR for having ESRD for cyclophosphamide versus corticosteroid is 0.49 (95% CrI 0.25–0.92), which is statistically significant. In this case, corticosteroid is the treatment diagonally above cyclophosphamide, and therefore serves as the reference treatment. Similarly, the OR of cyclophosphamide is 1.36 (95% CrI 0.11–1.50) compared with corticosteroid for having a malignancy, not statistically significant. ESRD: endstage renal disease; CrI: credible interval.